BACKGROUND: After allogeneic hematopoietic stem-cell transplantation patients are at increased risk for herpes zoster as long as varicella-zoster virus specific T-cell reconstitution is impaired. This study aimed to identify immunodominant varicella-zoster virus antigens that drive recovery of virus-specific T cells after transplantation. DESIGN AND METHODS: Antigens were purified from a varicella-zoster virus infected cell lysate by high-performance liquid chromatography and were identified by quantitative mass spectrometric analysis. To approximate in vivo immunogenicity for memory T cells, antigen preparations were consistently screened with ex vivo PBMC of varicella-zoster virus immune healthy individuals in sensitive interferon-γ ELISpot assays. Candidate virus antigens identified by the approach were genetically expressed in PBMC using electroporation of in vitro transcribed RNA encoding full-length proteins and were then analyzed for recognition by CD4(+) and CD8(+) memory T cells. RESULTS: Varicella-zoster virus encoded glycoproteins B and E, and immediate early protein 62 were identified in immunoreactive lysate material. Predominant CD4(+) T-cell reactivity to these proteins was observed in healthy virus carriers. Furthermore, longitudinal screening in allogeneic stem-cell transplantation patients showed strong expansions of memory T cells recognizing glycoproteins B and E after onset of herpes zoster, while immediate early protein 62 reactivity remained moderate. Reactivity to viral glycoproteins boosted by acute zoster was mediated by both CD4(+) and CD8(+) T cells. CONCLUSIONS: Our data demonstrate that glycoproteins B and E are major targets of varicella-zoster virus specific CD4(+) and CD8(+) T-cell reconstitution occurring during herpes zoster after allogeneic stem-cell transplantation. Varicella-zoster virus glycoproteins B and E might form the basis for novel non-hazardous zoster subunit vaccines suitable for immunocompromised transplant patients.
BACKGROUND: After allogeneic hematopoietic stem-cell transplantation patients are at increased risk for herpes zoster as long as varicella-zoster virus specific T-cell reconstitution is impaired. This study aimed to identify immunodominant varicella-zoster virus antigens that drive recovery of virus-specific T cells after transplantation. DESIGN AND METHODS: Antigens were purified from a varicella-zoster virus infected cell lysate by high-performance liquid chromatography and were identified by quantitative mass spectrometric analysis. To approximate in vivo immunogenicity for memory T cells, antigen preparations were consistently screened with ex vivo PBMC of varicella-zoster virus immune healthy individuals in sensitive interferon-γ ELISpot assays. Candidate virus antigens identified by the approach were genetically expressed in PBMC using electroporation of in vitro transcribed RNA encoding full-length proteins and were then analyzed for recognition by CD4(+) and CD8(+) memory T cells. RESULTS:Varicella-zoster virus encoded glycoproteins B and E, and immediate early protein 62 were identified in immunoreactive lysate material. Predominant CD4(+) T-cell reactivity to these proteins was observed in healthy virus carriers. Furthermore, longitudinal screening in allogeneic stem-cell transplantation patients showed strong expansions of memory T cells recognizing glycoproteins B and E after onset of herpes zoster, while immediate early protein 62 reactivity remained moderate. Reactivity to viral glycoproteins boosted by acute zoster was mediated by both CD4(+) and CD8(+) T cells. CONCLUSIONS: Our data demonstrate that glycoproteins B and E are major targets of varicella-zoster virus specific CD4(+) and CD8(+) T-cell reconstitution occurring during herpes zoster after allogeneic stem-cell transplantation. Varicella-zoster virus glycoproteins B and E might form the basis for novel non-hazardous zoster subunit vaccines suitable for immunocompromised transplant patients.
Authors: A M Arvin; M Sharp; S Smith; C M Koropchak; P S Diaz; P Kinchington; W Ruyechan; J Hay Journal: J Immunol Date: 1991-01-01 Impact factor: 5.422
Authors: Eva Distler; Elke Schnürer; Eva Wagner; Charis von Auer; Bodo Plachter; Daniela Wehler; Christoph Huber; Karin Kolbe; Ralf Georg Meyer; Wolfgang Herr Journal: Biol Blood Marrow Transplant Date: 2008-12 Impact factor: 5.742
Authors: Veronique Erard; Katherine A Guthrie; Cara Varley; Judson Heugel; Anna Wald; Mary E D Flowers; Lawrence Corey; Michael Boeckh Journal: Blood Date: 2007-05-21 Impact factor: 22.113
Authors: D Teschner; E Distler; D Wehler; M Frey; D Marandiuc; K Langeveld; M Theobald; S Thomas; W Herr Journal: Bone Marrow Transplant Date: 2013-08-12 Impact factor: 5.483
Authors: Marius Birlea; Gregory P Owens; Emily M Eshleman; Alanna Ritchie; Igor Traktinskiy; Nathan Bos; Scott Seitz; Yevgeniy Azarkh; Ravi Mahalingam; Don Gilden; Randall J Cohrs Journal: J Virol Date: 2012-10-17 Impact factor: 5.103
Authors: Kerry J Laing; Ronnie M Russell; Lichun Dong; D Scott Schmid; Michael Stern; Amalia Magaret; Jürgen G Haas; Christine Johnston; Anna Wald; David M Koelle Journal: J Infect Dis Date: 2015-03-17 Impact factor: 5.226
Authors: Janet J Sei; Kara S Cox; Sheri A Dubey; Joseph M Antonello; David L Krah; Danilo R Casimiro; Kalpit A Vora Journal: Front Immunol Date: 2015-10-29 Impact factor: 7.561
Authors: Benedict R Halbroth; Alexander Heil; Eva Distler; Martin Dass; Eva M Wagner; Bodo Plachter; Hans Christian Probst; Dennis Strand; Udo F Hartwig; Anita Karner; Gerald Aichinger; Otfried Kistner; Katharina Landfester; Wolfgang Herr Journal: PLoS One Date: 2014-07-29 Impact factor: 3.240